[Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial].
M
M
Sirakov
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002584:Cervix Uteri / Q000821:virology; D004311:Double-Blind Method; D005260:Female; D052162:Human papillomavirus 16 / Q000302:isolation & purification*; D052161:Human papillomavirus 18 / Q000302:isolation & purification*; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control* / Q000821:virology*
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D053918:Papillomavirus Vaccines